FDA 483 - Shandong Luxi Pharmaceutical Co., Ltd. - July 24, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Shandong Luxi Pharmaceutical Co. Ltd., an Active Pharmaceutical Ingredient (API) manufacturer in Heze City, China, revealed significant deficiencies in laboratory controls and data integrity. Observations included insufficient stability studies, inadequate maintenance of laboratory records and raw data, and a lack of proper procedures for electronic data review and system validation. These findings indicate a serious breakdown in the firm's quality control systems.
ID · cfffbb8f-a49e-48cd-8537-74cd7eb7312c